Amazon launches AI platform to accelerate drug discovery

Published: 2026-04-14 14:08:45 ET AMZN

Amazon, through its AWS subsidiary, has unveiled Amazon Bio Discovery, an artificial intelligence platform designed to expedite the early stages of pharmaceutical research. The tool enables scientists to execute complex workflows without programming, leveraging a library of biological models capable of generating and evaluating candidate molecules. An AI agent assists users in model selection, parameter tuning, and result analysis, amid intensifying competition surrounding the integration of AI in healthcare.

Esteban Tesson

Published on 04/14/2026 at 02:08 pm EDT

The platform operates on an iterative logic, where the most promising molecules are transmitted to partner laboratories for synthesis and testing, before the results are fed back into the system. According to AWS, a process that previously required 18 months to produce 300 candidate molecules can now be compressed into a few weeks. This acceleration, however, highlights a shortage of specialists capable of designing machine learning pipelines tailored to scientific objectives.Amazon emphasizes that this technology is intended to complement the work of researchers rather than replace it. Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics, while 19 of the top 20 pharmaceutical groups already utilize AWS cloud services. As part of a partnership with Memorial Sloan Kettering, the platform generated nearly 300,000 antibody molecules, narrowed down to 100,000 candidates tested in the lab within weeks. AWS also plans to offer a free trial and the future launch of tools dedicated to clinical trial optimization.